Selank: Anxiolytic Peptide Research and GABAergic Modulation

# Selank: Anxiolytic Peptide Research and GABAergic Modulation

For Research Purposes Only — Not Intended for Human or Animal Consumption

Introduction

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analogue of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) with immunomodulatory properties, extended with the sequence Pro-Gly-Pro to improve metabolic stability and CNS penetration.

Selank has been studied primarily for its anxiolytic properties and has been registered as a pharmaceutical in Russia for the treatment of anxiety disorders. The published research base — while largely from Russian institutions — includes both preclinical mechanistic studies and clinical trials, providing a more developed evidence base than many research peptides.

GABAergic Modulation

The primary proposed mechanism of Selank's anxiolytic effects involves modulation of the GABAergic system — the brain's primary inhibitory neurotransmitter system. GABA (gamma-aminobutyric acid) acts on GABA-A receptors, ligand-gated chloride channels that hyperpolarize neurons and reduce excitatory signaling.

Semenova et al. (2010) demonstrated that Selank increases the expression of GABA-A receptor subunits in the hippocampus and amygdala of rats — brain regions central to anxiety processing. This upregulation of GABA-A receptors would be expected to enhance GABAergic inhibition and produce anxiolytic effects.

Importantly, Selank's GABAergic effects appear to differ mechanistically from benzodiazepines, which act as positive allosteric modulators at the benzodiazepine binding site of GABA-A receptors. Selank appears to act through receptor expression modulation rather than direct receptor binding, which may explain the absence of tolerance and dependence observed in animal studies.

BDNF Upregulation

Selank has been shown to increase the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus. BDNF is a neurotrophin that supports neuronal survival, synaptic plasticity, and hippocampal neurogenesis. Reduced BDNF expression is associated with anxiety and depression in both animal models and human studies.

Inozemtseva et al. (2008) demonstrated that Selank administration increased hippocampal BDNF mRNA expression by approximately 40% in rats, an effect that persisted for at least 24 hours following a single administration. This BDNF upregulation may contribute to both the anxiolytic effects and potential neuroprotective properties of the peptide.

Enkephalin System Interactions

Research has also documented interactions between Selank and the enkephalin system — endogenous opioid peptides that modulate pain, mood, and stress responses. Selank appears to inhibit enkephalin-degrading enzymes, thereby increasing the availability of endogenous enkephalins.

This mechanism is pharmacologically distinct from exogenous opioids and does not involve direct opioid receptor agonism. The enhancement of endogenous enkephalin signaling may contribute to Selank's anxiolytic and mood-modulating effects without the addiction liability associated with opioid receptor agonists.

Clinical Research

Selank has been evaluated in several clinical trials conducted in Russia. Zozulya et al. (2001) conducted a randomized controlled trial in patients with anxiety disorders and demonstrated significant reductions in Hamilton Anxiety Scale scores compared to placebo, with an effect size comparable to benzodiazepines but without sedation or cognitive impairment.

A subsequent study by Semenova et al. (2009) examined Selank in patients with anxiety-asthenic disorders and reported improvements in both anxiety and cognitive performance measures, suggesting a combined anxiolytic-nootropic profile.

These clinical studies have methodological limitations including small sample sizes and limited geographic generalizability, and independent replication in Western clinical settings has not been conducted.

References

1. Semenova, T.P., et al. (2010). Selank and its analogue modulate the expression of genes involved in the regulation of the GABA system. Doklady Biochemistry and Biophysics, 432(1), 127–129.
2. Inozemtseva, L.S., et al. (2008). Systemic administration of the peptide selank influences the hippocampal BDNF expression in rats. Doklady Biological Sciences, 421(1), 241–243.
3. Zozulya, A.A., et al. (2001). The antiamnesic and anxiolytic effects of selank, a synthetic analogue of tuftsin. Bulletin of Experimental Biology and Medicine, 132(5), 1104–1107.